Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $8.35 and traded as high as $10.19. Grifols shares last traded at $10.08, with a volume of 529,870 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on GRFS shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Grifols in a report on Tuesday, August 5th. Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 7th. Zacks Research upgraded Grifols to a “hold” rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. upped their price objective on Grifols from $7.60 to $10.30 and gave the stock a “neutral” rating in a research report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.30.

Grifols Stock Performance

The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20. The company has a market cap of $6.93 billion, a PE ratio of 8.62, a PEG ratio of 0.35 and a beta of 0.56. The business’s 50 day moving average is $9.75 and its two-hundred day moving average is $8.35.

Grifols Announces Dividend

The business also recently declared a — dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols’s dividend payout ratio (DPR) is currently 11.97%.

Institutional Investors Weigh In On Grifols

A number of large investors have recently bought and sold shares of GRFS. Versant Capital Management Inc purchased a new stake in shares of Grifols in the first quarter valued at approximately $28,000. Tower Research Capital LLC TRC increased its stake in Grifols by 354.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 6,335 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after buying an additional 4,604 shares during the period. First Trust Advisors LP purchased a new position in shares of Grifols during the fourth quarter worth $75,000. Finally, Ballentine Partners LLC purchased a new position in shares of Grifols during the first quarter worth $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.